Quick Answer
Rein Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $3.22 million for the year ending 2025.
- Rein Therapeutics, Inc. showed a decrease of -75.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Rein Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: $3.89 million | Q3 2016: $4.50 million | Q2 2017: $9.40 million | Q3 2017: $13.43 million | Q1 2018: $6.78 million | Q2 2018: $11.98 million | Q3 2018: $7.72 million | Q1 2019: $11.27 million | Q2 2019: $10.16 million | Q3 2019: $6.87 million | Q1 2020: $10.70 million | Q2 2020: $17.12 million | Q3 2020: $7.85 million | Q1 2021: $19.28 million | Q2 2021: $10.75 million | Q3 2021: $7.60 million | Q1 2022: $7.45 million | Q2 2022: $7.63 million | Q3 2022: $4.84 million | Q1 2023: $7.78 million | Q2 2023: $13.17 million | Q3 2023: $12.07 million | Q1 2024: $12.04 million | Q2 2024: $21.92 million | Q3 2024: $17.65 million | Q1 2025: $7.43 million | Q2 2025: $5.72 million | Q3 2025: $4.05 million.
- Over the full 12 years of available data (2014 to 2025), Rein Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 48.2%.
- Historical annual values: Fiscal year 2025: $3.22 million | Fiscal year 2024: $12.87 million | Fiscal year 2023: $17.34 million | Fiscal year 2022: $5.19 million | Fiscal year 2021: $3.60 million | Fiscal year 2020: $7.05 million | Fiscal year 2019: $5.31 million | Fiscal year 2018: $10.64 million | Fiscal year 2017: $11.86 million | Fiscal year 2016: $20.72 million | Fiscal year 2015: $3.77 million | Fiscal year 2014: $6.21 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: